Evaluation of CAF22 After Renal Transplantation
Evaluation of Serum and Urinary C-terminal Agrin Fragment-22 (CAF22) as Novel Renal Function Marker in Kidney Transplant Recipients - A Prospective Observational Study
Sponsor: Insel Gruppe AG, University Hospital Bern
Listed as NCT02346968, this observational or N/A phase trial focuses on Delayed Graft Function and Kidney Transplantation and remains completed. Sponsored by Insel Gruppe AG, University Hospital Bern, it has been updated 13 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jul 2023 — Jul 2024 [monthly]
Completed
-
Dec 2021 — Jul 2023 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
▶ Show 8 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed
-
Sep 2019 — Nov 2020 [monthly]
Completed
Status: Recruiting → Completed
-
Jun 2018 — Sep 2019 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Nov 2017 — Apr 2018 [monthly]
Recruiting NA
-
Aug 2017 — Nov 2017 [monthly]
Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Recruiting NA
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Insel Gruppe AG, University Hospital Bern
For direct contact, visit the study record on ClinicalTrials.gov .